Castle Biosciences to Participate in Upcoming Investor Conferences
A live audio webcast of the Company’s presentation will be available on Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available for 90 days following the conclusion of the live broadcast.
Castle will also be available for one-on-one investor meetings during the 6th Annual
About
Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005116/en/
Investor Contact:
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: